Rate of detection of high-risk HPV with two assays in women≥30years of age

Journal of Clinical Virology

Volumn 52, Issue 1, 2011, Pages 23-27

  Quigley, Neil B ^a   Potter, Nicholas T ^a   Chivukula, Mamatha ^b   Knight, Mirna Z ^c   Welch, James R ^d   Olson, Marilyn C ^e  

^a Molecular Pathology Laboratory Network Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Metropolitan Pathologists   (United States)

^d Cytocheck Laboratory   (United States)

^e HOLOGIC INC   (United States)

Author keywords

Cervista; High risk; HPV; HPV test; Prevalence

Indexed keywords

ADULT; ARTICLE; BIOASSAY; CERVISTA TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HYBRID CAPTURE TEST; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; VIRUS DETECTION;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 79961127568     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.05.014     Document Type: Article

References (23)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
2. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
3. Bouvard V., Baan R., Straif K., et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009, 10(4):321-322.
4. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338(7):423-428.
5. Trottier H., Mahmud S.M., Lindsay L., et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 2009, 18(3):854-862.
6. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197(4):346-355.
7. ACOG Practice Bulletin No. 109, cervical cytology screening. Obstet Gynecol 2009, 114(6):1409-1420.
8. Cervista® HPV HR [package insert]. Marlborough, MA: Hologic, Inc; 2009 (P/N 15-3100).
9. CERVISTA® HPV 16/18 [package insert]. Marlborough, MA: Hologic, Inc; 2009 (P/N 15-3101).
10. Digene HC2 HPV DNA Test [package insert]. Gaithersburg, MD: Qiagen; 2007.
11. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009, 113(3):595-600.
12. Pirog E.C., Erroll M., Harigopal M., Centeno B.A. Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems. Arch Pathol Lab Med 2004, 128(5):527-532.
13. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244-265.
14. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287(16):2114-2119.
15. Eversole G.M., Moriarty A.T., Schwartz M.R., et al. Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med 2010, 134(3):331-335.
16. Genfind™ DNA Extraction Kit [package insert]. Madison, WI: Hologic, Inc; 2009 (P/N 15-3110). Web site: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm134056.htm.
17. Day S.P., Hudson A., Mast A., et al. Analytical performance of the Investigational use only cervista™ HPV HR test as determined by a multi-center study. J Clin Virol 2009, 45(S1):S63-S72.
18. Datta S.D., Koutsky L.A., Ratelle S., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008, 148(7):493-500.
19. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
20. Kinney W., Stoler M.H., Castle P.E. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010, 134(2):193-199.
21. Castle P.E., Solomon D., Wheeler C.M., et al. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008, 46(8):2595-2604.
22. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97(14):1072-1079.
23. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168(2):123-137.